1MICROMEDEX(R)[S].Healthcare Series Vol.124 quarter 2/2005
2ABRUZZO G K,FLATTERY AM,GILL C J,et al.Evaluation of the echinocandin antifungal MK-0991 (L-743,872):efficacies in mouse models of disseminated aspergillosis,candidiasis,and cryptococcosis[J].Antimicrob Agents Chemother,1997,41(11):2333-2338.
3ABRUZZO G K,GILL C J,FLATTERY A M,et al.Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice[J].Antimicrob Agents Chemother,2000,44 (9):2310-2318.
4HERNANDEZ S,SOPEZ-RIBOT J L,NAJVAR L K,et al.Caspofungin resistance in Candida albicans:correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis[J].Antimicrob Agents Chemother,2004,48(4):1382-1383.
5VILLANUEVA A,GOTUZZO E,ARATHOON E G,et al.A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis[J].Am J Med,2002,113:294-299.
6MORA-DUARTE J,BETTS R,ROTSTEIN C,et al.Comparison of caspofungin and amphotericin B for invasive candidiasis[J].N Engl J Med,2002,347:2020-2029.
7THOMAS J,WALSH M D,HEDY T,et al.Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia[J].N Engl J Med,2004,351 (9):1391-1402.
